USFDA concludes inspection at Solara's Cuddalore facility with Zero 483 inspectional observations

Solara Active Pharma Sciences Ltd (Solara) (NSE: SOLARA; BSE: 541540), a leading Active Pharmaceutical Ingredient / CRAMS company, today announced that its multiproduct manufacturing facility at Cuddalore, completed successfully the inspection carried out by the US Food and Drug Administration (US FDA or Agency). The Agency, with its designated investigators, inspected the Cuddalore facility between July 31, 2023 - August 04, 2023. The inspection established that the facility is in an "Acceptable State of Compliance" with Zero Form 483 inspectional observations from the Agency.

With this successful inspection outcome, the current inspection classification of Cuddalore site shall be reinstated to NAI (No Action Indicated).

This facility has also successfully completed the regulatory inspections carried out by the World Health Organization (WHO) between January 23 - 26, 2023 and EU-GMP Inspection carried out jointly by the "State Institute for Drug Control (SUKL), Ministry of Health of the Czech Republic" and "National Authority of Medicines and Health Products (INFARMED), Portugal" between February 07 - 09, 2023.

Poorvank Purohit (MD and CEO), commented, "We are happy with the outcome of the FDA inspection with Zero 483 inspectional observations. This is the third consecutive successful regulatory inspections outcome (USFDA, EU-GMP and WHO-GMP inspections) at our Cuddalore site and gives us confidence in our quality systems and oversight of our manufacturing infrastructure. The result of these inspections demonstrates our commitment to regulatory excellence at our global manufacturing sites and our relentless focus on world-class quality and compliance. We stay committed to exhibit the highest level of compliance and constant focus on world-class quality with the validated quality systems established across Solara's manufacturing network.

The Cuddalore multi-product API manufacturing facility was established in the year 1991 and is equipped with appropriate infrastructure to include several independent production blocks and related packaging sections. This site is inspected by various Regulatory Authorities including US FDA, MHRA, EDQM, WHO, PMDA, TGA, KFDA, and COFEPRIS.

Shares of Solara Active Pharma Sciences Limited was last trading in BSE at Rs. 393.10 as compared to the previous close of Rs. 393.00. The total number of shares traded during the day was 66236 in over 3981 trades.

The stock hit an intraday high of Rs. 399.60 and intraday low of 391.30. The net turnover during the day was Rs. 26205147.00.

Source : Equity Bulls

Keywords

SolaraActivePharmaSciences INE624Z01016 Cuddalore Multiproduct ManufacturingFacility USFDA Inspection